Sodium Channel

3- Deoxyaconitine is a derivative of Aconitine (A189875), which activates tetrodotoxin-sensitive Na+ channels, inducing presynaptic depolarization, thus

Applications Articaine is an amide based short-acting local anesthetic use for regional anaesthesia in day-case settings such arthroscopy, hand , food surgery and in dentistry. References Malamed, S.F., et al.: J. Am. Dent. Assoc., 132, 177 (2001); Luan, F., et al.: Bioorg. Med. Chem., 21, 1870 (2013);

Riluzole (RP-54274) is an anticonvulsant, glutamate antagonist, and prolongs ALS patient survival.

Impurity Lidocaine EP Impurity D (HCl) Applications Nor Lidocaine Hydrochloride is a hydrochloride salt metabolite of Lidocaine (L397800), an Anesthetic (local); antiarrhythmic (class IB). Long-acting, membrane stabilizing agent against ventricular arrhythmia. Originally developed as a local anesthetic Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Fukuda, S., et al.: Anesthesiology, 53, 106 (1980), Duce, R., et al.: J. Pharmacol. Exp. Ther., 179, 580 (1971); Kronberg, G.H., et al.: J. Med. Chem., 16, 739 (1973); Groningsson, K., et al.: Anal. Profiles Drug Subs., 14, 207 (1985); Davies, P.S., et al.: Drugs, 64, 937 (2004);

Permethrin (NRDC-143) is a pyrethroid insecticide commonly used in the treatment of LICE INFESTATIONS and SCABIES.

Nav1.3 Channel Inhibitor 1 (Compound 15b) is a state-dependent inhibitor of the voltage-gated sodium channel Na v 1.3, with an IC50 value of 20 nM.

Applications N-Formyl Benzocaine is a degradation product of Benzocaine (B202970); a compound that is used as an anesthetic (local). References Kholod, Y., et al.: Environ. Sci. Technol., 43, 9208 (2009); Fliri, A., et al.: J. Med. Chem., 52, 8038 (2009); Helguera, A., et al.: J. Pharm. Sci., 98, 4557 (2009); Onoue, S., et al.: J. Pharm. Sci., 98, 3647 (2009); Koellmer, M., et al.: AAPS PharmSciTech., 14, 1333 (2013)

Tocainide is a blocker of the sodium channel and used for the treatment of tinnitus.

PF-01247324 is a selective and orally bioavailable Nav1.8 channel blocker (IC50: 196 nM).

Applications N-(4-Bromo-2,6-dimethylphenyl)-2-chloroacetamide is a useful synthetic intermediate in the synthesis of 4-Hydroxylidocaine (H943825); a metabolite of Lidocaine (L397800) which is a common local anesthetic and antiarrhythmic drug. References Duce, R., et al.: J. Pharmacol. Exp. Ther., 179, 580 (1971); Kronberg, G.H., et al.: J. Med. Chem., 16, 739 (1973); Groningsson, K., et al.: Anal. Profiles Drug Subs., 14, 207 (1985); Davies, P.S., et al.: Drugs, 64, 937 (2004)

Benzocaine shares a common receptor with all othe rLAs in the voltage-gated Na+ channel(IC50 of 0.8 mM tested with a potential of +30 mV).

Nav1.7 inhibitor is a Nav1.7 inhibitor for research in the field of pain and anesthesia.

PF-05186462 (PF-05150122) is a potent, state-dependent, subtype selective Nav1.7 inhibitor with IC50 of 21 nM, no significant activity against Nav1.5.

Applications 5-Hydroxy Propafenone Hydrochloride-d5 is a labeled analogue of 5-Hydroxy Propafenone Hydrochloride (H952450), a metabolite of Propafenone (P757500), a sodium channel blocker. Antiarrhythmic (class IC). References Hege, H.G., et al.: Eur. J. Drug Metab. Pharmacokinet., 9, 41 (1984); Hollmann, M., et al.: Arzneim.-Forsch., 33, 763 (1983); Bryson, H. M., et al.:Drugs, 45, 85 (1993); Rae, A. P., et al.: Am. J. Cardiol., 82, 59N (1998)

Rimeporide hydrochloride (EMD-87580 hydrochloride) is a potent and selective Sodium hydrogen exchange 1 (NHE-1) inhibitor.

solpecainol is a sodium channel blocker used in the study of neurological and cardiovascular diseases.

E 0747 FA is an antiarrhythmic compound that inhibits the voltage of action potential Vmax in Purkinje fibers of porcine heart.E 0747 FA inhibits Na channels in cardiac cells.

Applications Anesthetic (local); antiarrhythmic (class IB). Long-acting, membrane stabilizing agent against ventricular arrhythmia. Originally developed as a local anesthetic. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Duce, R., et al.: J. Pharmacol. Exp. Ther., 179, 580 (1971), Kronberg, G.H., et al.: J. Med. Chem., 16, 739 (1973), Groningsson, K., et al.: Anal. Profiles Drug Subs., 14, 207 (1985), Davies, P.S., et al.: Drugs, 64, 937 (2004),